Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effect of Thymoquinone 0.2% Gel on Bone Density, Bone Width, and Socket Preservation After Tooth Extraction

NCT07765745 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-02-01
Last updated
2026-08-14

Condition(s) studied

Radiographic EvaluationBone DensityBone WidthSocket PreservationTooth ExtractionThymoquinone

Investigational drug(s) / intervention(s)

Gel foamThymoquinone gel + gel foamNano-formulated 0.2% thymoquinone gel + gel foam

Gel foam: Patients will receive gel foam only.

Thymoquinone gel + gel foam: Patients will receive 0.2% thymoquinone gel + gel foam.

Nano-formulated 0.2% thymoquinone gel + gel foam: Patients will receive nano-formulated 0.2% thymoquinone gel + gel foam.

Study summary

This study aims to evaluate the clinical and radiographic effects of 0.2% Thymoquinone gel on bone density, bone width, and socket preservation after tooth extraction.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Age: 18-50 years. * Both sexes. * Patients requiring extraction of upper posterior teeth will be recruited. Exclusion Criteria: * Healthy subjects with intact sockets after extraction. * Normal mouth opening and good oral hygiene. * No systemic conditions affecting bone healing.

Primary outcome measure(s)

  • Change in alveolar bone density after tooth extraction — 3 months after tooth extraction
    Alveolar bone density will be assessed radiographically using cone-beam computed tomography (CBCT). The change in bone density from baseline to the specified postoperative assessment will be compared.

Trial sites (1)

FacilityCityRegionStatus
Kafrelsheikh University Kafr ash Shaykh Kafrelsheikh Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07765745 on ClinicalTrials.gov ↗ ← All trials in Egypt